Tag Archive for: radioligand therapies

Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc., a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.

Eli Lilly on Tuesday announced it is acquiring Point Biopharma in an effort to bolster its cancer business with the Pennsylvania-based company’s pipeline of clinical and preclinical radioligand therapies.

The companies have reached a deal to discover and develop several targeted radioligand therapies in oncology.